Brokerages Set Zoetis Inc. (NYSE:ZTS) PT at $152.91

Shares of Zoetis Inc. (NYSE:ZTS) have been given a consensus rating of “Hold” by the thirteen brokerages that are covering the company, MarketBeat Ratings reports. Eight research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $152.9091.

Several equities research analysts recently commented on the stock. UBS Group decreased their price objective on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 5th. Bank of America downgraded shares of Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 price target on the stock. in a report on Monday, December 15th. Wall Street Zen raised shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Friday. BTIG Research reaffirmed a “buy” rating and issued a $160.00 target price on shares of Zoetis in a research note on Wednesday, December 3rd. Finally, KeyCorp began coverage on Zoetis in a report on Thursday, November 20th. They set a “sector weight” rating on the stock.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $123.89 on Friday. The firm has a market capitalization of $54.60 billion, a price-to-earnings ratio of 20.86, a price-to-earnings-growth ratio of 2.15 and a beta of 0.97. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.64 and a quick ratio of 2.28. The business’s 50 day simple moving average is $123.68 and its 200-day simple moving average is $137.91. Zoetis has a 12 month low of $115.25 and a 12 month high of $177.40.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.08. The firm had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.Zoetis’s quarterly revenue was up .5% on a year-over-year basis. During the same period last year, the business posted $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities analysts forecast that Zoetis will post 6.07 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 3rd. Investors of record on Tuesday, January 20th will be paid a dividend of $0.53 per share. The ex-dividend date of this dividend is Tuesday, January 20th. This is an increase from Zoetis’s previous quarterly dividend of $0.50. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.7%. Zoetis’s dividend payout ratio is 35.69%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Scott & Selber Inc. raised its position in shares of Zoetis by 0.6% in the second quarter. Scott & Selber Inc. now owns 11,652 shares of the company’s stock valued at $1,817,000 after buying an additional 67 shares during the last quarter. North Star Asset Management Inc. grew its stake in Zoetis by 4.9% in the 2nd quarter. North Star Asset Management Inc. now owns 1,441 shares of the company’s stock worth $225,000 after acquiring an additional 67 shares during the period. Moment Partners LLC raised its holdings in Zoetis by 3.2% in the 2nd quarter. Moment Partners LLC now owns 2,354 shares of the company’s stock valued at $367,000 after acquiring an additional 72 shares during the last quarter. CVA Family Office LLC lifted its stake in shares of Zoetis by 6.7% during the 2nd quarter. CVA Family Office LLC now owns 1,173 shares of the company’s stock worth $183,000 after purchasing an additional 74 shares during the period. Finally, Bank of Nova Scotia Trust Co. boosted its holdings in shares of Zoetis by 4.6% during the second quarter. Bank of Nova Scotia Trust Co. now owns 1,692 shares of the company’s stock worth $264,000 after purchasing an additional 74 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.